UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated April 9, 2019
(Commission File No. 001-31269)
Alcon Inc.
(Name of Registrant)
Rue Louis-d’Affry 6
1701 Fribourg
Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F: x |
| Form 40-F: o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes: o |
| No: x |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes: o |
| No: x |
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes: o |
| No: x |
Exhibit |
|
|
Number |
| Description |
|
|
|
99.1 |
| Separation and Distribution Agreement by and between Novartis AG and Alcon Inc., dated as of April 8, 2019 |
99.2 |
| Tax Matters Agreement by and between Novartis AG and Alcon Inc., dated as of April 8, 2019 |
99.3 |
| Employee Matters Agreement by and between Novartis AG and Alcon Inc., dated as of April 8, 2019 |
99.4 |
| Forward Manufacturing and Supply Agreement by and between Novartis Pharma AG and Alcon Inc., dated as of April 8, 2019 |
99.5 |
| Reverse Manufacturing and Supply Agreement by and between Novartis Pharma AG and Alcon Inc., dated as of April 8, 2019 |
99.6 |
| Transitional Services Agreement by and between Novartis AG and Alcon Inc., dated as of April 8, 2019 |
99.7 |
| Patent and Know-How License Agreement by Novartis AG for the benefit of Alcon Inc., dated as of April 8, 2019 |
99.8 |
| Patent and Know-How License Agreement by Alcon Inc. for the benefit of Novartis AG, dated as of April 8, 2019 |
99.9 |
| Brand License Agreement by Novartis AG for the benefit of Alcon Inc., dated as of April 8, 2019 |
99.10 |
| Brand License Agreement by Alcon Inc. for the benefit of Novartis AG, dated as of April 8, 2019 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alcon Inc. | |
|
|
|
|
|
|
Date: April 9, 2019 | By: | /s/ David J. Endicott |
| Name: | David J. Endicott |
| Title: | Authorized Representative |
| By: | /s/ Royce Bedward |
| Name: | Royce Bedward |
| Title: | Authorized Representative |